Pay in 4 interest-free payments of $5.08 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Dastgerdi AH, Rad MG, Soltani N
We did not identify any study that specifically addressed potential interactions between GLP-1RAs and frequently used antidepressant medications
Arcutis disclosed aggregated results from the Phase III INTEGUMENT-1 and INTEGUMENT-2 trials in January 2024, revealing that 91.5% of atopic dermatitis patients treated with the drug showed measurable improvement in the Eczema Area and Severity Index (EASI) score after four weeks
Albion and TRAACS are registered trademarks of Albion Laboratories, Inc
However, adverse GI effects, particularly nausea, constipation, and dyspepsia, remain notable considerations
The Bottom Line GLP-1 medications represent one of the most significant developments in obesity and chronic disease management in decades
